Amanote Research
Register
Sign In
Inhibition of Phosphotyrosine Phosphatase 1B Causes Resistance in BCR-ABL-Positive Leukemia Cells to the ABL Kinase Inhibitor STI571
Clinical Cancer Research
- United States
doi 10.1158/1078-0432.ccr-04-2392
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Oncology
Date
April 1, 2006
Authors
N. Koyama
Publisher
American Association for Cancer Research (AACR)
Related search
Effect of a Selective Abl Tyrosine Kinase Inhibitor, STI571, on in Vitro Growth of BCR-ABL-positive Acute Lymphoblastic Leukemia Cells
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Tyrosine Kinase Inhibitors in BCR-ABL Positive Acute Lymphoblastic Leukemia
Haematologica
Hematology
BCR-ABL Tyrosine Kinase
Science-Business eXchange
Protein Kinase CKIIa Interacts With the BCR Moiety of BCR/Abl and Mediates Proliferation of BCR/Abl-Expressing Cells
Oncogene
Cancer Research
Genetics
Molecular Biology
Contribution of BCR-ABL Kinase Domain Mutations to Imatinib Mesylate Resistance in Philadelphia Chromosome Positive Malaysian Chronic Myeloid Leukemia Patients
Hematology Reports
Hematology
Bcr: A Negative Regulator of the BCR-Abl Oncoprotein in Leukemia
Oncogene
Cancer Research
Genetics
Molecular Biology
Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia
Cancer Research
Cancer Research
Oncology
A Non-Atp-Competitive Inhibitor of BCR-ABL Overrides Imatinib Resistance
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
WNT/Ca2+/Nfat Signaling Maintains Survival of Ph+ Leukemia Cells Upon Inhibition of BCR-Abl
Cancer Cell
Cancer Research
Oncology
Cell Biology
